Choosing the Right Liver; Organ Allocation and Matching

Charles M. Miller, MD
Professor of Surgery
Director of Liver Transplantation
Cleveland Clinic
Matching

- **Choice of Liver**
  1. Standard DBD
  2. Partial liver
  3. DCD
  4. HCV +ve donor
  5. “Aggressive offer”

- **Recipient factors**
  1. Body size and ascites
  2. Portal hypertension
  3. Surgical risk (PVT, Re-LT)
  4. HCV vs. other
  5. “Hot list”
Matching

Choice of Liver
1. Standard DBD
2. Partial liver
3. DCD
4. HCV +ve donor
5. “Aggressive offer”

Recipient factors
1. Body size and ascites
2. Portal hypertension
3. Surgical risk (PVT, Re-LT)
4. HCV vs. other
5. “Hot list”

Patients with low MELD but is symptomatic or has HCC beyond Milan criteria, thus willing to accept marginal grafts.
Gap between supply and demand

Data from 2009 OPTN/SRTR Annual Report, AJT Wertheim 2011
Figure IV-4. Unadjusted Death Rates per 1,000 Patient-Years at Risk, 1998-2007, Liver Waiting List

Source: 2008 OPTN/SRTR Annual Report, Table 9.3.
Alternative liver grafts in US 1999-2008

Data from 2009 OPTN/SRTR Annual Report, AJT Wertheim 2011
Matching

**Choice of Liver**
1. Standard DBD
2. Partial liver
3. DCD
4. HCV +ve donor
5. “Aggressive offer”

**Recipient factors**
1. Body size and ascites
2. Portal hypertension
3. Surgical risk (PVT, Re-LT)
4. HCV vs. other
5. “Hot list”
Split Transplantation in US

- Survey for split liver transplant, 4/00-3/01
  - 207 LLS, 152 RTS, 15 left lobe, and 13 right lobe grafts
    *Ann Surg, Renz, 2004*

- 1260 Pediatric LT for <12 yo recipient, 2/02-12/04
  - 52% received whole liver transplantation
  - 33% SLT
  - 15% LDLT
    *Liver Transplant, Becker, 2008*
LDLT vs. cadaveric graft: Advantages and Disadvantages

Advantages

- Assures a healthy organ with minimal preservation damage
- Independence from long cadaveric waiting list
- Optimizes the timing of transplantation
- Helps alleviate the severe shortage of cadaveric livers and death on the waiting list

Disadvantages

- Finite risk of donor morbidity and mortality
- Both operation are technically complex
- The program is extremely labor-intensive
- Reputational risk
Split vs. whole liver graft: Advantages and Disadvantages

Advantages
- Assures a healthy organ with minimal preservation damage
- Independence from long cadaveric waiting list
- Optimizes the timing of transplantation
- Helps alleviate the severe shortage of cadaveric livers and death on the waiting list

Disadvantages
- Finite risk of donor morbidity and mortality
- Both operation are technically complex
- The program is extremely labor-intensive
- Reputational risk
Ideal Candidates for LDLT

1. Patients who has live donors
2. Pediatric patients (Anonymous donor)
3. Patients with lower MELD who need to wait long but are suffering from symptoms
   - Refractory ascites
   - Encephalopathy

- Exclusion in Cleveland Clinic

1. Re-LT
2. Kidney failure
Right vs. Left Lobe in LDLT

- Depends on **graft size** and **severity of portal hypertension**

---

**Cut1, Right Lobe Graft without MHV**

<table>
<thead>
<tr>
<th>Territory</th>
<th>Volume</th>
<th>Relative (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutting Plane</td>
<td>10 ml</td>
<td>&lt; 1.0</td>
</tr>
<tr>
<td>Graft</td>
<td>696 ml</td>
<td>57.8</td>
</tr>
<tr>
<td>Remnant</td>
<td>495 ml</td>
<td>41.2</td>
</tr>
<tr>
<td>Total</td>
<td>1296 ml</td>
<td>100.0</td>
</tr>
</tbody>
</table>

Minimal deviations can be caused by rounding errors.

The estimated graft weight is about 635 g.

**Key Figures**

<table>
<thead>
<tr>
<th>Ratio</th>
<th>Based On</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graft Recipient Body Weight Ratio</td>
<td>Estimated Graft Weight</td>
<td>0.67</td>
</tr>
<tr>
<td>Graft Recipient Body Weight Ratio</td>
<td>Graft Volume</td>
<td>0.96</td>
</tr>
<tr>
<td>Graft to SLV Ratio</td>
<td>Estimated Graft Weight</td>
<td>0.49</td>
</tr>
<tr>
<td>Graft to SLV Ratio</td>
<td>Graft Volume</td>
<td>0.54</td>
</tr>
</tbody>
</table>
Splittable Donor

1. Donor age less than 40 years
2. Stable systemic hemodynamics
3. Normal gross appearance of the liver during organ procurement.
   - Liver biopsy as needed.
   - Macrosteatosis < 20%
Ideal Candidates for Split - 1st half of hemi-liver

1. Got an offer of good donor, but big
2. Recipient with standard surgical risk
   - Avoid re-LT, or extensive PVT
Ideal Candidates for Split - 2nd half of hemi-liver

1. Smaller patients
   - <70%, <100% of donor BW for L, and R lobe
2. Recipient with standard surgical risk
3. Not much portal hypertension
4. (With good portosystemic shunt)

Other consideration
1. Man power (Young Attendings in town?)
2. Patients who don’t have live donors
Ideal Candidates for Right Trisegment Split

1. Anybody who needs liver transplant
Question -1

32 year-old male. 180cm, 120kg (5’10”, 264 lbs), BMI 37. Drinker 5 beer/day. COD Trauma. Brain dead 2 days after admission. Platelet at admission was 150 K, and now 70K. Normal LFTs. Had transfusions but now hemodynamically stable.

Here is your center’s allocation list. What would you do?

<table>
<thead>
<tr>
<th>#1</th>
<th>MELD 28</th>
<th>56 yo F, PBC, minimal Portal HTN</th>
<th>160cm, 56 kg (5’ 3”, 123 lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>Other center</td>
<td>********************</td>
<td>********************</td>
</tr>
<tr>
<td>#3</td>
<td>MELD 26</td>
<td>65 y/o M, PCS, minimal PHT</td>
<td>180cm, 120kg (5’ 10”, 264 lbs)</td>
</tr>
</tbody>
</table>
Split Liver Transplantation Using Hemiliver Graft in the MELD Era: A Single Center Experience in the United States


Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH
*Corresponding author: Koji Hashimoto, hashimk@ccf.org
### Split Donor Demographics

**Table 2: Donor demographics**

<table>
<thead>
<tr>
<th></th>
<th>Hemiliver (n = 16)</th>
<th>Whole liver (n = 121)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>22 (11–39)</td>
<td>27 (10–40)</td>
<td>0.14</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>16 (100.0%)</td>
<td>85 (70.2%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>180 (170–193)</td>
<td>175 (120–203)</td>
<td>0.02</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>89 (38–115)</td>
<td>77 (24–143)</td>
<td>0.11</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.0 (13.1–33.5)</td>
<td>24.6 (17.2–48.8)</td>
<td>0.69</td>
</tr>
<tr>
<td>Vasopressor use</td>
<td>12 (75.0%)</td>
<td>67 (55.4%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Cause of death</td>
<td></td>
<td></td>
<td>0.97</td>
</tr>
<tr>
<td>Trauma</td>
<td>13 (81.3%)</td>
<td>95 (78.5%)</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular</td>
<td>2 (12.5%)</td>
<td>18 (14.9%)</td>
<td></td>
</tr>
<tr>
<td>Anoxia</td>
<td>1 (6.3%)</td>
<td>8 (6.6%)</td>
<td></td>
</tr>
<tr>
<td>Serum sodium</td>
<td>152 (139–172)</td>
<td>147 (125–167)</td>
<td>0.02</td>
</tr>
<tr>
<td>ALT</td>
<td>36 (17–442)</td>
<td>37 (3–1357)</td>
<td>0.51</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>1.0 (0.4–2.0)</td>
<td>0.8 (0.2–5.3)</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Hashimoto et al. AJT 2014
Good matching to get an appropriate GRWR
Question -1

32 year-old male. 180cm,120kg (5’10”, 264 lbs), BMI 37.
Drinker 5 beer/day. COD Trauma. Brain dead 2 days after admission.
Platelet at admission was 150 K, and now 70K.
Normal LFTs. Had transfusion but now hemodynamically stable.
Here is allocation list. What would you do?

<table>
<thead>
<tr>
<th>#1</th>
<th>MELD 28</th>
<th>56 yo F, PBC, some PHTN</th>
<th>160cm, 56 kg (5’ 3”, 123 lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>Other center</td>
<td>**********************</td>
<td>**********************</td>
</tr>
<tr>
<td>#3</td>
<td>MELD 26</td>
<td>65 yo M, HCV, severe PHTN</td>
<td>180cm, 120kg (5’ 10”, 264 lbs)</td>
</tr>
</tbody>
</table>

1. Decline for #1. Liver would be fatty. Also I don’t think #2 in the other center is such big.
2. Accept for #1 for left lobe, and admit #3 for right lobe.
3. Accept for #1 for left lobe, and admit #3 for back up.
What would you do?

A. Decline for #1. Liver will be fatty. Also I don’t think #2 in the other center is so big; therefore we will get it for #3.

B. Accept for #1 for left lobe, and admit #3 for right lobe.

C. Accept for #1 for left lobe, and admit #3 for back up if liver is marginal and #2 declines.
Matching

- **Choice of Liver**
  1. Standard DBD
  2. Partial liver
  3. DCD
  4. HCV +ve donor
  5. “Aggressive offer”

- **Recipient factors**
  1. Body size and ascites
  2. Portal hypertension
  3. Surgical risk (PVT, Re-LT)
  4. HCV vs. other
  5. “Hot list”
Over the last decade, controlled DCD liver transplantation has been a fast growing source of liver grafts in Europe and the US

<table>
<thead>
<tr>
<th>Category</th>
<th>Alternative categorization</th>
<th>Status of potential donor</th>
<th>Hospital department</th>
<th>Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Uncontrolled</td>
<td>Dead upon arrival</td>
<td>Accident and emergency</td>
<td>Viability testing</td>
</tr>
<tr>
<td>II</td>
<td>Uncontrolled</td>
<td>Resuscitation attempted without success</td>
<td>Accident and emergency</td>
<td>Viability testing</td>
</tr>
<tr>
<td>III</td>
<td>Controlled</td>
<td>Awaiting cardiac arrest</td>
<td>Intensive care</td>
<td>Transplantation</td>
</tr>
<tr>
<td>IV</td>
<td>Controlled</td>
<td>Cardiac arrest while brain dead</td>
<td>Intensive care</td>
<td>Transplantation</td>
</tr>
</tbody>
</table>
DCD grafts are associated with increased incidence of PNF, HAT or ischemic cholangiopathy.

If in a DBD the organ makes a single step from warm oxygenated and metabolically active to cold, hypoxic and metabolically inactive the DCD organ at the time of X-clamp has already suffered from a period of hypotension/hypoxia followed by the cardiac arrest.
DCD

How to improve the outcome?

Limit the donor warm ischemia time (DWIT)

1. Huddle with the local hospital personnel (where patient will be extubated; assess men power to move the donor from ICU during the “no touch time”; surgical prep and drape during the “no touch” time)

2. Experienced surgeon to perform the “super-rapid technique”

3. Discard livers with in situ WIT > 30min
DCD

The “super rapid technique”

Figure 1.
The super-rapid technique. Midline abdominal incision and aortic cannulation for immediate perfusion of cold preservation solution.

Figure 2.
Sternal-splitting, thoracic aorta cross-clamping and intrapericardial inferior vena cava venting.

DCD

Each minute increase in the asystole-to-cross clamp duration is associated with a 16.1% increase in the odds for the development of ischemic cholangiopathy or hepatic necrosis.

The goal of the rapid procurement technique is to clear the blood from the peribiliary arterioles in a rapid manner.

Figure 1 Different time points during procurement.

Table 3. Comparison of procurement time points in DCD liver grafts with diagnosis of ITBS versus no ITBS (seven patients who had HAT and five patients who had PNFs were excluded from analysis).

<table>
<thead>
<tr>
<th></th>
<th>No ITBS</th>
<th>ITBS</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>DCD WIT</td>
<td>24.31 ± 8.70 (18, 24, 30)</td>
<td>24.41 ± 7.67 (19, 24, 30)</td>
<td>0.756</td>
</tr>
<tr>
<td>Withdrawal-asystole</td>
<td>15.36 ± 8.55 (10, 14, 19)</td>
<td>14.42 ± 6.07 (9.75, 13, 19)</td>
<td>0.819</td>
</tr>
<tr>
<td>Asystole-cross clamp</td>
<td>8.81 ± 3.27 (7, 8, 11)</td>
<td>10.65 ± 3.96 (8, 10, 12.25)</td>
<td></td>
</tr>
<tr>
<td>Hypotensive WIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withdrawal-SBP &lt; 50</td>
<td>10.24 ± 8.42 (5, 9, 14)</td>
<td>10.39 ± 56.8 (6, 10, 15)</td>
<td>0.405</td>
</tr>
<tr>
<td>SBP &lt; 50 - Asystole</td>
<td>5.2 ± 5.09 (1, 3, 8)</td>
<td>3.35 ± 4.59 (1, 3, 5)</td>
<td>0.176</td>
</tr>
<tr>
<td>SBP &lt; 50 - cross clamp</td>
<td>14.13 ± 5.84 (10, 13, 17)</td>
<td>14.26 ± 4.84 (11, 13, 17)</td>
<td>0.839</td>
</tr>
<tr>
<td>Hypoxic WIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withdrawal-O2 Sat &lt; 30</td>
<td>8.19 ± 7.03 (4, 6, 11)</td>
<td>8.76 ± 5.71 (4, 7, 12.5)</td>
<td>0.483</td>
</tr>
<tr>
<td>O2 Sat &lt; 30 - asystole</td>
<td>7.51 ± 6.12 (3, 7, 11)</td>
<td>5.67 ± 4.28 (2, 4, 9.5)</td>
<td>0.305</td>
</tr>
<tr>
<td>O2 Sat &lt; 30 - cross clamp</td>
<td>16.52 ± 6.75 (11, 16, 21)</td>
<td>16.52 ± 5.29 (12, 16, 19.5)</td>
<td>0.998</td>
</tr>
</tbody>
</table>

Values in minutes, presented as mean ± SD (25th, 50th, 75th percentile).

Bold values indicates significant at P < 0.05.
**DCD**

**How to improve the outcome?**

Best donor-recipient match

1. Cut off of the DCD donor age?
2. Avoid “redo” or recipient on life support at the time of transplant

---

**TABLE 2. Multivariate Cox proportional hazards model of risk factors for graft loss and DCD risk index**

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Coefficient</th>
<th>95% confidence interval</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recipient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous transplant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.692</td>
<td>1.997 (1.318–3.027)</td>
<td>0.001</td>
</tr>
<tr>
<td>Life support at transplantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>Yes</td>
<td>0.632</td>
<td>1.882 (1.241–2.854)</td>
<td></td>
</tr>
<tr>
<td>Donor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 45 )</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45–60</td>
<td>0.314</td>
<td>1.369 (1.027–1.825)</td>
<td>0.032</td>
</tr>
<tr>
<td>( &gt; 60 )</td>
<td>0.569</td>
<td>1.766 (1.076–2.900)</td>
<td>0.025</td>
</tr>
<tr>
<td>Donor warm ischemic time (minutes)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 15 )</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15–30</td>
<td>0.315</td>
<td>1.370 (1.037–1.809)</td>
<td>0.027</td>
</tr>
<tr>
<td>( &gt; 30 )</td>
<td>0.576</td>
<td>1.780 (1.137–2.785)</td>
<td>0.012</td>
</tr>
<tr>
<td>Cold ischemic time (hours)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq 10 )</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>( &gt; 10 )</td>
<td>0.284</td>
<td>1.329 (1.001–1.763)</td>
<td>0.049</td>
</tr>
</tbody>
</table>

DCD risk index = \( \exp\left(0.692 \text{ previous transplant (TX) history} + 0.632 \text{ if on life support} + 0.314 \text{ if donor age \( \leq 60 \)} + 0.569 \text{ if donor age > 60} + 0.315 \text{ if warm ischemic time \( \leq 30 \)} + 0.576 \text{ if warm ischemic time > 30} + 0.284 \text{ if CIT > 10}\right)\).
DCD

How to improve the outcome?
Minimize the cold ischemia time (CIT)

1. Select recipient with standard technical difficulty
   - No previous liver surgery or transplant
   - Avoid the case with concern in portal inflow

2. Start the recipient sooner
How to improve the outcome?
Consider improved liver preservation (TPA etc..)

Table 5. Strategies to optimize the outcome of DCD liver transplantation along the timeline of the different steps during the course of organ donation, preservation and transplantation and their status (clinically applied vs. preclinical status).

<table>
<thead>
<tr>
<th>Time period</th>
<th>Principle</th>
<th>Solution</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor</td>
<td>Donor pretreatment</td>
<td>Discard livers with <em>in situ</em> warm ischaemia &gt;30 minutes</td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Avoid extended warm ischaemia time</td>
<td></td>
<td>Ethically difficult</td>
</tr>
<tr>
<td>Flush-out</td>
<td>Improve complete flush-out of the microcirculation</td>
<td>Warm prefibrinolytic pre-flush</td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Initial flush with low viscosity preservation solution</td>
<td></td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Final flush-out with UW (high viscosity-gold standard preservation solution)</td>
<td></td>
<td>Clinically applied</td>
</tr>
<tr>
<td>Preservation</td>
<td>Limit cold ischaemia</td>
<td>Allocation of the liver to the procuring transplant center</td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Transplant livers as soon as possible</td>
<td></td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Select a recipient in whom the hepatectomy is expected to be of short duration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternative cold perfusion solutions</td>
<td>Cytoprotective additives to the perfusion solution</td>
<td>Preclinical status</td>
</tr>
<tr>
<td></td>
<td><em>Ex vivo</em> preservation by machine perfusion</td>
<td>Oxygenated hypothermic machine perfusion preservation</td>
<td>Preclinical status but clinically applied in a safety and feasibility trial for normal livers</td>
</tr>
<tr>
<td></td>
<td>Hypothermic oxygenated machine perfusion preservation</td>
<td></td>
<td>Preclinical status</td>
</tr>
<tr>
<td></td>
<td><em>Ex vivo</em> normothermic liver perfusion</td>
<td></td>
<td>Preclinical status</td>
</tr>
<tr>
<td></td>
<td><em>In vivo</em> normothermic liver perfusion using ECMO</td>
<td></td>
<td>Clinically applied</td>
</tr>
<tr>
<td>Recipient</td>
<td>Select a recipient who may tolerate dysfunction</td>
<td></td>
<td>Clinically applied</td>
</tr>
<tr>
<td></td>
<td>Reducing the ischaemia reperfusion injury</td>
<td>Multi-factorial biological modulation strategy</td>
<td>Preclinical status</td>
</tr>
</tbody>
</table>
Question -2

20 year-old male, football player, BMI 29 in ICU with ALF due to acetaminophen intoxication.
Intubated and sedated, clinical condition rapidly deteriorating, small pressors requirement, INR 6, Bil 10, sCr 1.5 MELD 39.
PMH negative
You have been offered, simultaneously:
#1. 25 yo DCD, car accident, no PMH, LFTs WNL, BMI 25
#2. 62 yo DBD, trauma, mild transaminitis, BMI 32, Type 2 DM and hypertension
Considering that size is not an issue, which would you choose? Unfortunately, you cannot accept both at this time.
Which would you choose?

A. Accept #1
B. Accept #2
C. Decline both
Answer

Accept #2 because the risk of PNF is lower as well as the risk of a bad IR related intraoperative coagulopathy. Moreover 1 might not expire!

Remember, the best DCD is a defacto extended criteria donor and, considering the concept of donor risk index, DCD liver are associated with a greater risk of graft failure when compared to 60-70 donor age.

Our recipient is rapidly deteriorating therefore waiting is not an option.
Matching

- Choice of Liver
  1. Standard DBD
  2. Partial liver
  3. DCD
  4. HCV +ve donor
  5. “Aggressive offer”

- Recipient factors
  1. Body size and ascites
  2. Portal hypertension
  3. Surgical risk (PVT, Re-LT)
  4. HCV vs. other
  5. “Hot list”
Hepatitis C and Liver Transplant

- HCV among the most common causes of liver disease worldwide
- HCV prevalence in USA: 1.6% of population
- HCV infection causes 20% of acute and 70% of chronic hepatitis.
- The most common indication for OLT for now, but not in near future.
- Patient and graft survival rates comparable with other indication for OLT.

Recurrence of Hepatitis C post-OLT

- Almost universal
- Progression is variable:
  - 70% develop mild fibrosis
  - 25% progress to cirrhosis within 5 years of LT
  - 5% develop fibrosing cholestatic hepatitis (FCH)
  - Grafts from older donors (>50 years old) associated with lower patient and graft survival
  - HCV recurrence lowers graft and patient survival rates.

Liver allografts from HCV positive donors

- With background of donor shortage, HCV +ve donor has become one of the important ECDs: up to 1.7 % of all successful OLTs
- Recipients of HCV +ve grafts: slightly older (age 51.8 years), have higher prevalence of pre-transplant HCC (8.9% vs 6.6 %)
- HCV + donors: older (41.4 vs 37 yo), CVA and anoxia were most common cause of death.
- HCV + organs: more likely to exported to other UNOS regions (20.1 vs 7.5 %)

Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV + allografts Liver Transpl. 2006 12: 1496-1503
Liver allografts from HCV positive donors

- No statistical difference in 5 year survival in HCV recipients using HCV + or HCV – allografts.
- Recipients of HCV + grafts from older donors (>50 yo) have higher rates of death and graft failure, and develop more extensive fibrosis.
- Donor HCV status is not an independent predictor of mortality after liver transplantation.

Dramatic Advance in the Treatment for Recurrent HCV

“There are decades where nothing happens; and there are weeks where decades happen”

Vladimir Ilyich Lenin
Treatment of HCV Post-OLT


SVR rate%

IFN  IFN+RBV  PegIFN  Peg-IFN+RBV  SOV+RBV  SOV+PI

PI = Protease Inhibitor (talepravir, bocepravir or now ledipasvir)
SOF + RBV to Prevent Recurrence of HCV post-OLT

- Recurrence of HCV post-OLT in 10/38 (26%)
- No recurrence in 24/25 (96%) of patients who maintained negative HCV RNA >4 weeks prior to OLT

Question -3

Donor offer of 55 year old female HCV Ab +ve DBD. Liver Bx showed mild inflammation with periportal fibrosis. Mild elevation of transaminase but normal bili. Platelet count at admission was 140 K.

Which HCV RNA +ve recipient(s) is/are suitable for the donor?

<table>
<thead>
<tr>
<th></th>
<th>MELD</th>
<th>genotype</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>44 yo M</td>
<td>35</td>
<td>IFN failure, HCV RNA+ve</td>
</tr>
<tr>
<td>B</td>
<td>54 yo M</td>
<td>18</td>
<td>SOF-RBV started 2 months ago with significant reduction in viral load</td>
</tr>
<tr>
<td>C</td>
<td>56 yo F</td>
<td>26</td>
<td>IFN failure, HCV RNA+ve</td>
</tr>
</tbody>
</table>
Which **HCV RNA +ve** recipient(s) is/are suitable for the donor?

<table>
<thead>
<tr>
<th></th>
<th>MELD</th>
<th>genotype</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>44 yo M</td>
<td>35</td>
<td>1a, IFN failure, HCV RNA+ve</td>
</tr>
<tr>
<td>B</td>
<td>54 yo M</td>
<td>18</td>
<td>1b, SOF-RBV started 2 months ago with significant reduction in viral load</td>
</tr>
<tr>
<td>C</td>
<td>56 yo F</td>
<td>26</td>
<td>3, IFN failure, HCV RNA+ve</td>
</tr>
</tbody>
</table>

A. A
B. B
C. A and B
D. B and C
E. None
### Answer

1. A

<table>
<thead>
<tr>
<th></th>
<th>MELD</th>
<th>genotype</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>44 yo M</td>
<td>35</td>
<td>1a</td>
</tr>
<tr>
<td>B</td>
<td>54 yo M</td>
<td>18</td>
<td>1b</td>
</tr>
<tr>
<td>C</td>
<td>56 yo F</td>
<td>26</td>
<td>3</td>
</tr>
</tbody>
</table>
Matching

- **Choice of Liver**
  1. Standard DBD
  2. Partial liver
  3. DCD
  4. HCV +ve donor
  5. “Aggressive offer”

- **Recipient factors**
  1. Body size and ascites
  2. Portal hypertension
  3. Surgical risk (PVT, Re-LT)
  4. HCV vs. other
  5. “Hot list”
Re-OLTX

It is already complicated. Select non-complicated donor.

Volumetry of recipient liver is useful to determine the acceptable size of donors.

A small patient with splenomegaly awaiting 3rd re-do.
Liver volume is 1300 mL
Matching

- **Choice of Liver**
  1. Standard DBD
  2. Partial liver
  3. DCD
  4. HCV +ve donor
  5. “Aggressive offer”

- **Recipient factors**
  1. Body size and ascites
  2. Portal hypertension
  3. Surgical risk (PVT, Re-LT)
  4. HCV vs. other
  5. “Hot list”
“Aggressive offer”

- Marginal donors who are likely to be turned down by many centers
  - Aged DBD (>75 y.o.) with extensive cardiovascular history
  - Aged DCD (>55 y.o.), DCD with high BMI (>40)
  - Concern of transmittable disease (meningitis, infection, brain tumor)
  - Offer from donor OR
    - Before or after X clamp

- Often from other OPO

- Many cases become “open offer”
  - Because all other center turned down, you can use the liver for anybody you want.
Who should receive “aggressive offer”? 

- If the risk is acceptable for regular patients, accept for them.
- Great opportunity for patients on “hot list”
- Offer from donor OR
  - Try to delay X clamp if it is not done
  - Find a suitable recipient who:
    1. lives close to the hospital,
    2. has a standard surgical risk, and
    3. doesn’t have blood antibody
**Question**

64 YO M, HCV, Blood type B with MELD 17. Six admissions (2 in ICU) in the last year for encephalopathy due to large splenorenal shunt. Now admitted in your hospital. Waiting LT for 2 years, now on “hot list”.

170 cm, 67 kg (5’7”, 147 lbs). No PVT or previous surgery. Needs 4 hrs to get blood ready.

Which donors are suitable for him with 10 patients being on the waiting list above him?

<table>
<thead>
<tr>
<th></th>
<th>Left-lobe split</th>
<th>34 yo M, 165 cm, 70 kg (5’5”, 154 lbs) (Est. L-lobe 620 g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Left-lobe split</td>
<td>34 yo M, 165 cm, 70 kg (5’5”, 154 lbs) (Est. L-lobe 620 g)</td>
</tr>
<tr>
<td>B</td>
<td>DCD</td>
<td>58 yo M, 165 cm, 65 kg (5’5”, 143 lbs), BMI 24</td>
</tr>
<tr>
<td>C</td>
<td>DCD</td>
<td>35 yo M, 160 cm, 103 kg (5’3”, 227 lbs), BMI 40</td>
</tr>
<tr>
<td>D</td>
<td>DBD, 3hrs after X clamp</td>
<td>57 yo, liver 2.6 kg, macrosteatosis 30-40%, Standard HA anatomy. Liver at the hospital across the road</td>
</tr>
</tbody>
</table>
Which donors do you think are suitable for him with 10 patients being on the waiting list above him?

A | Left-lobe split | 34 yo M, 165 cm, 70 kg (5’5”, 154 lbs) (Est. L-lobe 620 g)
B | DCD | 58 yo M, 165 cm, 65 kg (5’5”, 143 lbs), BMI 24
C | DCD | 35 yo M, 160 cm, 103 kg (5’3”, 227 lbs), BMI 40
D | DBD, 3hrs after X clamp | 57 yo, liver 2.6 kg, macrosteatosis 30-40%, Standard HA anatomy. Liver at the hospital across the road

A. A
B. A and B
C. A, B and C
D. B and C
E. All
A) Good match. GRWR of 0.92 is acceptable with a large shunt.
B) Controversial. Depends on program. May be a good chance for him.
C) When liver is not fatty, good enough for regular patients above him on the list.
D) Seems to be very high risk of PNF and too big liver for him. Big fatty liver with prolonged CIT and possibly poor inflow are bad combinations.

My answer is 2) A and B.
Conclusions

• In the background of high mortality rate on the waiting list of LT, it is crucial to use aggressively the alternative organ pool including partial liver, DCD, and “high risk donor”.

• Partial liver transplant can be done with favorable outcome by good donor-recipient pairing.

• DCD LT reportedly has inferior graft outcome, but can be improved with careful donor and recipient selection in addition to fundamental efforts including shortening canulation time in donor, and total CIT.
Conclusions

• The recent advance in HCV treatment has potential to rewrite the strategy of LT for HCV. The fear of graft failure from recurrent HCV is significantly decreased. There will be much less HCV +ve recipients in near future.

• It is imperative to maximize the effort to provide the chance of transplant to low MELD patients who have significant complications.
Table 4: Recipient demographics

<table>
<thead>
<tr>
<th></th>
<th>Hemiliver (n = 25)</th>
<th>Whole liver (n = 121)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)(^1)</td>
<td>56 (13–75)</td>
<td>55 (18–77)</td>
<td>0.8</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>20 (80.0%)</td>
<td>33 (27.3%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Height (cm)(^1)</td>
<td>158 (114–180)</td>
<td>173 (145–203)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight (kg)(^1)</td>
<td>58 (25–101)</td>
<td>88 (41–160)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m(^2))(^1)</td>
<td>24.2 (16.3–39.5)</td>
<td>29.1 (17.6–49.4)</td>
<td>0.001</td>
</tr>
<tr>
<td>Underlying liver disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral hepatitis</td>
<td>4 (16.0%)</td>
<td>92 (76.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alcoholic</td>
<td>3 (12.0%)</td>
<td>6 (5.0%)</td>
<td></td>
</tr>
<tr>
<td>Cryptogenic/NASH</td>
<td>3 (12.0%)</td>
<td>13 (10.7%)</td>
<td></td>
</tr>
<tr>
<td>PBC/PSC/AIH</td>
<td>7 (28.0%)</td>
<td>5 (4.1%)</td>
<td></td>
</tr>
<tr>
<td>Fulminant hepatic failure</td>
<td>1 (4.0%)</td>
<td>1 (0.8%)</td>
<td></td>
</tr>
<tr>
<td>Metabolic disorder</td>
<td>3 (12.0%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>4 (16.0%)</td>
<td>4 (3.3%)</td>
<td></td>
</tr>
<tr>
<td>Donor risk index(^1)</td>
<td>1.60 (1.31–2.02)</td>
<td>1.10 (0.87–1.65)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cold ischemia time (min)(^1)</td>
<td>390 (248–592)</td>
<td>421 (150–840)</td>
<td>0.3</td>
</tr>
<tr>
<td>Chemical MELD score(^1)</td>
<td>17 (7–26)</td>
<td>18 (6–43)</td>
<td>0.1</td>
</tr>
<tr>
<td>Listing MELD score(^1)</td>
<td>22 (14–28)</td>
<td>21 (10–40)</td>
<td>0.8</td>
</tr>
<tr>
<td>Platelet count (×10(^3)/μL)(^1)</td>
<td>98 (30–651)</td>
<td>73 (13–422)</td>
<td>0.001</td>
</tr>
<tr>
<td>Albumin (g/dL)(^1)</td>
<td>3.2 (2.0–4.5)</td>
<td>3.0 (1.5–4.9)</td>
<td>0.2</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)(^1)</td>
<td>3.2 (0.2–27.7)</td>
<td>3.2 (0.2–32.6)</td>
<td>0.4</td>
</tr>
<tr>
<td>Serum sodium (mEq/L)(^1)</td>
<td>137 (124–147)</td>
<td>137 (119–148)</td>
<td>0.9</td>
</tr>
<tr>
<td>Creatinine (mg/dL)(^1)</td>
<td>0.64 (0.35–11.01)</td>
<td>1.00 (0.41–11.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>INR(^1)</td>
<td>1.3 (0.6–2.1)</td>
<td>1.3 (0.9–3.7)</td>
<td>0.5</td>
</tr>
</tbody>
</table>